Stem cell antigen-1+ cell-based bone morphogenetic protein-4 gene transfer strategy in mice failed to promote endosteal bone formation

Journal of Gene Medicine

Volumn 11, Issue 10, 2009, Pages 877-888

  Hall, Susan L ^a,b   Chen, Shin Tai ^a,b   Gysin, Reinhard ^a,b   Gridley, Daila S ^b   Mohan, Subburaman ^a,b   Lau, K H William ^a,b  

^a Jerry L Pettis Memorial VA Medical Center   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone morphogenetic protein 4; Endosteal bone formation; Ex vivo; Gene therapy; Hematopoietic stem cells; Mice; Sca 1+ cell

Indexed keywords

ALKALINE PHOSPHATASE; BETA GALACTOSIDASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; FIBROBLAST GROWTH FACTOR 2; LENTIVIRUS VECTOR; MESSENGER RNA; STEM CELL ANTIGEN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MINERAL; CELL TRANSPLANTATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EMBRYO; ENGRAFTMENT; ENZYME ACTIVITY; EX VIVO STUDY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TRABECULAR BONE;

ANIMALS; ANTIGENS, LY; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MEMBRANE PROTEINS; MICE; OSTEOGENESIS; OSTEOPOROSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC;

MUS;

EID: 72449132451     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1369     Document Type: Article

References (45)

1. Bouxsein ML. Biomechanics of age-related fractures. In Osteoporosis, 2nd edn, Marcus R, Feldman D, Kelsey J (eds), Vol.1. Academic Press: San Diego, CA, 2001; 509-531.
2. Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 2006; 22: 919-928. (Pubitemid 43875559)
3. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039.
4. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441. (Pubitemid 32402100)
5. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148: 197-213. (Pubitemid 351665507)
6. Cosman F. Anabolic therapy for osteoporosis: parathyroid hormone. Curr Osteoporos Rep 2005; 3: 143-149.
7. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for two years and relevance to human safety. Toxicol Pathol 2008; 30: 312-321.
8. + cell-based bone marrow transplantation model for use in geneand cell-based therapeutic studies. Acta Haematol 2007; 117: 24-33.
9. Spangrude GI, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood 1995; 85: 1006-1016.
10. + hematopoietic cell-based gene therapy with a modified FGF-2 gene increased endosteal/trabecular bone formation in mice. Mol Therapy 2007; 15: 1881-1889.
11. Ryoo HM, Lee MH, Kim YJ. Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene 2006; 366: 51-57.
12. Einhorn TA, Majeska RJ, Mohaideen A, et al. A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fractures fracture repair. J Bone Joint Surg Am 2003; 85: 1425-1435. (Pubitemid 36951125)
13. Rundle CH, Miyakoshi N, Kasukawa Y, et al. In vivo bone formation in fracture repair by direct retroviral-based gene therapy with BMP-4. Bone 2003; 32: 591-601.
14. Gysin R, Wergedal JE, Sheng MH-C, et al. Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in rats. Gene Therapy 2002; 9: 991-999. (Pubitemid 34893583)
15. Peng H, Chen S-T, Wergedal JE, et al. Development of an MFG-based retroviral vector system for high secretion of functionally active human BMP-4. Mol Therapy 2001; 4: 95-104. (Pubitemid 32776500)
16. Reith AD, Rottapel R, Giddens E, et al.Wmutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev 1990; 4: 390-400. (Pubitemid 20105587)
17. Geissler EN, Russell ES. Analysis of the hematopoietic effects of new dominant spotting (W) mutations of themouse. 1. Influence upon hematopoietic stem cells. Exp Hematol 1983; 11: 452-460.
18. Soper BW, Duffy TM, et al. A genetically myeloablated MPS VII model detects the expansion and curative properties of as few as 100 enriched murine stem cells. Exp Hematol 1999; 27: 1691-1704
19. Chen S-T, Gysin R, Kapur S, Baylink DJ, Lau K-HW. Modifications of the fibroblast growth factor-2 gene led to a marked enhancement in secretion and stability of the recombinant fibroblast growth factor-2 protein. J Cell Biochem 2007; 100: 1493-1508. (Pubitemid 46515581)
20. Yam PY, Li S, Wu J, et al. Design of LV vectors for efficient gene delivery into human hematopoietic cells. Mol Therapy 2002; 5: 479-484. (Pubitemid 34308674)
21. ΔΔC T method. Methods 2001; 25: 402-408.
22. Rundle CH, Strong DD, Chen S-T, et al. Retroviral-based gene therapy with cyclooxygenase-2 promotes the union of bony callus tissues and accelerates fracture healing in the rat. J Gene Med 2008; 10: 229-241.
23. Farley JR, Hall SL, Herring S, Tarbaux NM. Two biochemical indices of mouse bone formation are increased, in vivo, in response to calcitonin. Calcif Tissue Int 1992; 50: 67-73.
24. Wergedal JE, Ackert-Bicknell CL, Tsaih S-W, et al. Femur mechanical properties in the F2 progeny of an NZB/B1NJ x RF/J cross are regulated predominantly by genetic loci that regulate bone geometry. J Bone Miner Res 2006; 21: 1256-1266.
25. Bai Y, Soda Y, Izawa K, et al. Effective transduction and stable transgene expression in human blood cells by a third-generation lentivial vector. Gene Therapy 2003; 10: 1446-1457. (Pubitemid 36987138)
26. Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000; 78: 476-486. (Pubitemid 30491075)
27. NishimuraR, KatoY, ChenD, et al. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 1998; 273: 1872-1879.
28. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994; 127: 1755-1766. (Pubitemid 24380911)
29. Zhang XS, Linkhart TA, Chen S-T, et al. Local ex vivo gene therapywith bonemarrow stromal cells expressing human BMP4 promotes endosteal bone formation in mice. J Gene Med 2004; 6: 4-15.
30. Rundle CH, Chen S-T, Porte R, Wergedal JE, Lau K-HW. Retroviral-based BMP-4 in vivo gene transfer strategy with intramedullary viral delivery optimizes transgene expression in rat femur fractures. Open Tissue Eng Regener Med J 2008; 1: 14-22.
31. Jung Y, Song J, Shiozawa Y, et al. Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells 2008; 26: 2042-2051.
32. Katoh Y, Katoh M. Comparative genomics on BMP4 othrologs. Int J Oncol 2005; 27: 581-585.
33. Varkey M, Kucharski C, Hague T, Sebald W, Uludaǧ H. In vitro osteogenic response of rat bonemarrow cells to bFGF and BMP-2 treatments. Clin Orthop Relat Res 2006; 443: 113-123. (Pubitemid 44324941)
34. Varkey M, Kucharski C, Doschak MR, et al. Osteogenic response of bone marrow stromal cells from normal and ovariectomized rats treated with a low dose of basic fibroblast growth factor. Tissue Eng 2007; 13: 809-817. (Pubitemid 46651511)
35. Herford AS, Boyne PJ. Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2). J Oral Maxillofac Surg 2008; 66: 616-624.
36. Benavente CA, Sierralta WD, Conget PA, Minguell JJ. Subcellular distribution and mitogenic effect of basic fibroblast growth factor in mesenchymal uncommitted stem cells. Growth Factors 2003; 21: 87-94. (Pubitemid 37369352)
37. Bianchi G, Banfi A, Mastrgiacomo M, et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res 2003; 287: 98-105. (Pubitemid 36683205)
38. BaddooM, HillK, WilkinsonR, et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem 2003; 89: 1235-1249. (Pubitemid 36959389)
39. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178. (Pubitemid 40616114)
40. Carvalho RS, Einhorn TA, Lehmann W, et al. The role of angiogenesis in amurine tibialmodel of distraction osteogenesis. Bone 2004; 34: 849-861. (Pubitemid 38581131)
41. Mair B, Fuerst G, Kubitzky P, et al. The anti-angiogenic substance TNP-470 impairs peri-implant bone formation: a pilot study in the rabbit metaphysis model. Clin Oral Implants Res 2007; 18: 370-375.
42. Deckers MM, van Bezooijen RL, van der Horst G, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002; 143: 1545-1553. (Pubitemid 34274386)
43. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 2000; 21: 393-411. (Pubitemid 32275586)
44. Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 2002; 110: 751-759. (Pubitemid 35050952)
45. Shore EM, Kaplan FS. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone 2008; 43: 427-433.